首页 | 本学科首页   官方微博 | 高级检索  
     

重庆市耐多药结核分枝杆菌对贝达喹啉和德拉马尼的药物敏感性研究
引用本文:罗明,张汇征,严晓峰,曹培明,廖传玉,何瑛,李晓旭,王静,李同心,陈耀凯. 重庆市耐多药结核分枝杆菌对贝达喹啉和德拉马尼的药物敏感性研究[J]. 中国人兽共患病杂志, 2020, 36(2): 100-104. DOI: 10.3969/j.issn.1002-2694.2020.00.024
作者姓名:罗明  张汇征  严晓峰  曹培明  廖传玉  何瑛  李晓旭  王静  李同心  陈耀凯
作者单位:重庆市公共卫生医疗救治中心,重庆 400036
基金项目:“十三五”国家科技重大专项(No.2018ZX10302104);重庆市科卫联合医学科研项目(No.2019MSXM023)。
摘    要:目的分析重庆市耐多药结核分枝杆菌(multidrug-resistant Mycobacterium tuberculosis,MDR-TB)对贝达喹啉(bedaquiline,Bdq)和德拉马尼(delamanid,Dlm)的药物敏感性,以期为临床上Bdq和Dlm的合理使用提供参考。方法收集2017年11月至2018年11月间经重庆市公共卫生医疗救治中心鉴定为MDR-TB的菌株,采用微孔板法测定Bdq和Dlm的最低抑菌浓度(minimum inhibitory concentration, MIC),并对相关结果进行分析。结果所收集的111例MDR-TB临床分离株进行Bdq的药敏检测结果显示, MIC50和MIC90分别为0.016 mg/L和0.125 mg/L;109例MDR-TB菌株的Dlm药敏结果显示,MIC50和MIC90分别为0.016 mg/L和0.063 mg/L。各有5株菌株对Bdq和Dlm耐药,耐药率分别为4.50%和4.59%。不同耐药情况分组对Bdq和Dlm的耐药率与MDR...

关 键 词:重庆市  耐多药结核分枝杆菌  贝达喹啉  德拉马尼  药物敏感性
收稿时间:2019-08-26

Analysis of drug-susceptibility of bedaquiline and delamanid against multidrug-resistant Mycobacterium tuberculosis in Chongqing
LUO Ming,ZHANG Hui-zheng,YAN Xiao-feng,CAO Pei-ming,LIAO Chuan-yu,HE Ying,LI Xiao-xu,WANG Jing,LI Tong-xin,CHEN Yao-kai. Analysis of drug-susceptibility of bedaquiline and delamanid against multidrug-resistant Mycobacterium tuberculosis in Chongqing[J]. Chinese Journal of Zoonoses, 2020, 36(2): 100-104. DOI: 10.3969/j.issn.1002-2694.2020.00.024
Authors:LUO Ming  ZHANG Hui-zheng  YAN Xiao-feng  CAO Pei-ming  LIAO Chuan-yu  HE Ying  LI Xiao-xu  WANG Jing  LI Tong-xin  CHEN Yao-kai
Affiliation:Chongqing Public Health Medical Center, Chongqing 400036, China
Abstract:This study is aimed to analyze the drug-susceptibility of bedaquiline and delamanid in multidrug-resistant Mycobacterium tuberculosis in Chongqing,in order to provide reference for the proper use of bedaquiline and delamanid in clinical treatment.A total of 111 MDR-TB strains isolated from Chongqing Public Health Medical Center during Nov.2017 to Nov.2018 were collected.Minimum inhibitory concentrations(MIC)of Bdq and Dlm against these isolates were detected and analyzed.Drug susceptibility test of Bdq for 111 MDR-TB isolates with the MIC 50 and MIC 90 was 0.016 mg/L and 0.125 mg/L,and drug resistant rate of Bdq was 4.50%(5/111).Drug susceptibility test of Dlm for 109 MDR-TB isolates indicated that the MIC 50 and MIC 90 was 0.016 mg/L and 0.063 mg/L,and drug resistant rate of Dlm was 4.59%(5/109).There was no significant difference in Bdq and Dlm resistance between MDR-TB and the other groups of different drug resistance.In conclusion,most of the MDR-TB clinical isolates in Chongqing are susceptible to Bdq and Dlm,however,primary resistance has been already existed.Therefore,it is still necessary to pay attention to the drug susceptibility test of new drugs when developing MDR-TB treatment regimens.
Keywords:Chongqing  multidrug-resistance Mycobacterium tuberculosis  bedaquiline  delamanid  drug-susceptibility
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国人兽共患病杂志》浏览原始摘要信息
点击此处可从《中国人兽共患病杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号